LU92912I2 - Mépolizumab et ses dérivés pharmaceutiquement acceptables (nucala) - Google Patents

Mépolizumab et ses dérivés pharmaceutiquement acceptables (nucala) Download PDF

Info

Publication number
LU92912I2
LU92912I2 LU92912C LU92912C LU92912I2 LU 92912 I2 LU92912 I2 LU 92912I2 LU 92912 C LU92912 C LU 92912C LU 92912 C LU92912 C LU 92912C LU 92912 I2 LU92912 I2 LU 92912I2
Authority
LU
Luxembourg
Prior art keywords
pct
nucala
mepolizumab
pharmaceutically acceptable
acceptable derivatives
Prior art date
Application number
LU92912C
Other languages
English (en)
French (fr)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27408594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92912(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,420 external-priority patent/US5683892A/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of LU92912I2 publication Critical patent/LU92912I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
LU92912C 1994-12-23 2015-12-16 Mépolizumab et ses dérivés pharmaceutiquement acceptables (nucala) LU92912I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36313194A 1994-12-23 1994-12-23
US08/467,420 US5683892A (en) 1994-12-23 1995-06-06 DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US08/470,110 US5693323A (en) 1994-12-23 1995-06-06 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
PCT/US1995/017082 WO1996021000A2 (en) 1994-12-23 1995-12-22 Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders

Publications (1)

Publication Number Publication Date
LU92912I2 true LU92912I2 (fr) 2016-02-16

Family

ID=27408594

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92912C LU92912I2 (fr) 1994-12-23 2015-12-16 Mépolizumab et ses dérivés pharmaceutiquement acceptables (nucala)

Country Status (21)

Country Link
US (1) US6129913A (cg-RX-API-DMAC7.html)
EP (1) EP0800536B1 (cg-RX-API-DMAC7.html)
JP (2) JP2001523083A (cg-RX-API-DMAC7.html)
CN (1) CN100391977C (cg-RX-API-DMAC7.html)
AT (1) ATE346867T1 (cg-RX-API-DMAC7.html)
AU (1) AU708951B2 (cg-RX-API-DMAC7.html)
BR (1) BR9510499B1 (cg-RX-API-DMAC7.html)
CA (1) CA2208503C (cg-RX-API-DMAC7.html)
CZ (1) CZ297045B6 (cg-RX-API-DMAC7.html)
DE (1) DE69535319T2 (cg-RX-API-DMAC7.html)
DK (1) DK0800536T3 (cg-RX-API-DMAC7.html)
ES (1) ES2277336T3 (cg-RX-API-DMAC7.html)
FI (1) FI119374B (cg-RX-API-DMAC7.html)
HU (1) HU222992B1 (cg-RX-API-DMAC7.html)
LU (1) LU92912I2 (cg-RX-API-DMAC7.html)
MX (1) MX9704779A (cg-RX-API-DMAC7.html)
NL (1) NL300787I1 (cg-RX-API-DMAC7.html)
NO (2) NO324181B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ301916A (cg-RX-API-DMAC7.html)
PL (1) PL194312B1 (cg-RX-API-DMAC7.html)
WO (1) WO1996021000A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN1326879C (zh) * 2002-03-29 2007-07-18 先灵公司 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
EP1682571A4 (en) * 2003-10-27 2006-12-06 Medvet Science Pty Ltd BICOORDIN PATTERN AND METHODS OF USE
ATE541585T1 (de) 2004-10-28 2012-02-15 Kyowa Hakko Kirin Co Ltd Antikörper gegen il-5-rezeptor zur verwendung in der behandlung von endometriose.
SI2152290T1 (sl) 2007-04-30 2014-09-30 Glaxosmithkline Llc Postopki za dajanje anti-IL-5 protiteles
JP4335286B2 (ja) 2008-02-08 2009-09-30 ファナック株式会社 部品保護機能を備えたロボット制御装置及びロボット制御方法
JP5917143B2 (ja) 2008-03-28 2016-05-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 処置方法
MA34004B1 (fr) * 2010-01-28 2013-02-01 Glaxo Group Ltd Protéines de liaison à cd127
MX2013007392A (es) 2010-12-22 2013-11-01 Cephalon Australia Pty Ltd Anticuerpo modificado con vida media mejorada.
AU2016311385C1 (en) 2015-08-24 2019-08-22 Glaxosmithkline Intellectual Property (No.2) Limited Biopharmaceutical compositions
WO2017173091A1 (en) * 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
AR110564A1 (es) 2016-12-23 2019-04-10 Cephalon Inc Anticuerpos anti-il-5
MX2019014105A (es) * 2017-05-26 2020-02-07 Glaxosmithkline Ip Dev Ltd Composiciones biofarmaceuticas y metodos relacionados.
KR102709785B1 (ko) * 2017-09-29 2024-09-24 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Ｉｌ－５ 항체, 이의 항원 결합 단편 및 이의 의학적 적용
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
EP3896085A4 (en) * 2018-12-12 2022-11-30 Shanghai Pharmaexplorer Co., Ltd. MONOCLONAL ANTIBODY TO HUMAN INTERLEUKIN 5 (IL-5) AND ITS USE
EP3939611A4 (en) * 2019-03-29 2022-12-21 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY AND USE THEREOF
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
EP0441891A1 (en) * 1988-11-03 1991-08-21 Schering Corporation Method of preventing or reducing eosinophilia
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA929328B (en) * 1991-12-02 1993-07-20 Fluor Corp Apparatus and method for economic use of excess compressed air when firing low caloric-value gas in a combustion gas turbine.
AR248044A1 (es) * 1992-02-06 1995-05-31 Schering Corp Una secuencia de adn que codifica anticuerpos monoclonales humanizados contra interleuquinas humanas, metodo de obtencion y de seleccion de dichos anticuerpos, vector recombinante y celula huesped.
JPH06141885A (ja) * 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
WO1995014040A1 (en) * 1993-11-19 1995-05-26 Baylor College Of Medicine Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
WO2001012646A1 (en) * 1999-08-19 2001-02-22 Smithkline Beecham Corporation Sialoadhesin factor-1 agonist and antagonist antibodies

Also Published As

Publication number Publication date
NO972913L (no) 1997-08-19
EP0800536A4 (en) 2004-12-01
WO1996021000A2 (en) 1996-07-11
ATE346867T1 (de) 2006-12-15
ES2277336T3 (es) 2007-07-01
BR9510499B1 (pt) 2009-05-05
CA2208503C (en) 2009-12-01
AU4745096A (en) 1996-07-24
CN100391977C (zh) 2008-06-04
MX9704779A (es) 1997-09-30
NL300787I2 (cg-RX-API-DMAC7.html) 2016-04-05
HUT78055A (hu) 1999-07-28
BR9510499A (pt) 1999-03-30
WO1996021000A3 (en) 1996-09-06
CA2208503A1 (en) 1996-07-11
NO972913D0 (no) 1997-06-20
JP2001523083A (ja) 2001-11-20
DK0800536T3 (da) 2007-04-02
AU708951B2 (en) 1999-08-19
FI119374B (fi) 2008-10-31
US6129913A (en) 2000-10-10
NL300787I1 (cg-RX-API-DMAC7.html) 2016-04-05
FI972703A0 (fi) 1997-06-23
EP0800536A2 (en) 1997-10-15
PL194312B1 (pl) 2007-05-31
NZ301916A (en) 1999-05-28
JP2008029355A (ja) 2008-02-14
HK1003651A1 (en) 1998-11-06
FI972703L (fi) 1997-08-22
CZ196397A3 (en) 1997-10-15
DE69535319D1 (de) 2007-01-11
PL321088A1 (en) 1997-11-24
DE69535319T2 (de) 2007-07-19
NO2015027I2 (no) 2016-01-04
EP0800536B1 (en) 2006-11-29
NO2015027I1 (no) 2015-12-18
NO324181B1 (no) 2007-09-03
HU222992B1 (hu) 2004-01-28
CN1175263A (zh) 1998-03-04
CZ297045B6 (cs) 2006-08-16

Similar Documents

Publication Publication Date Title
LU92912I2 (fr) Mépolizumab et ses dérivés pharmaceutiquement acceptables (nucala)
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
PL320064A1 (en) Application of dioxomorpholines for fighting against endoparasites, novel dioxomorphoines and method of obtaining them
FI970147A0 (fi) Triatsoliyhdisteitä ja niiden käyttö dopamiini-D3-ligandeina
FI955389A0 (fi) Tandskyddande profylaktisk preparat och administreringsmedlen emot mellanoerpatogener
ES2132415T3 (es) Nuevos derivados de 5-pirrolil-2-piridilmetilsulfinilbencimidazol.
FR2721608B1 (fr) Dérivés de thiazolidine, leur préparation et les médicaments les contenant.
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
DE69715841D1 (de) Phosphatidsäure enthaltende zusammensetzungen
DE69513837D1 (de) Cyklopeptolide
PT728138E (pt) Derivados de antraciclina
DK0823909T3 (da) Hidtil ukendte heterocykliske forbindelser
ATE216891T1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
PL318459A1 (en) N-substituted derivatives of azabicycoheptane, method of obtaining them and their application
IL117083A (en) Pyridine and pyridazine derivatives processes for the production thereof and pharmaceutical compositions containing these compounds
NO974687L (no) Kondenserte <beta>-carboliner